Physician profile
Jonathan Byers
NPI 1821385733
$13,620.43
in general payments reported to CMS, 2019-2025
52 companies · $2,552 in 2025
The $2,552 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,748 · 2020: $1,443 · 2021: $1,685 · 2022: $1,521 · 2023: $2,161 · 2024: $2,510 · 2025: $2,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,223.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,112.85 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,399.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,210.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $879.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $869.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $751.28 | 2019-2025 | |
| Amgen INC. | $651.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $488.68 | 2019-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $422.34 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.73 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $352.86 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $348.83 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $285.04 | 2019-2022 | |
| Axsome Therapeutics, INC. | $276.23 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $260.84 | 2019-2025 | Myrbetriq, Veozah |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.27 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $201.43 | 2019-2025 | Verquvo, Lagevrio |
| Supernus Pharmaceuticals, INC. | $194.29 | 2019-2025 | Qelbree, Qelbree |
| Phathom Pharmaceuticals, INC. | $191.77 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $191.12 | 2021 | |
| Amarin Pharma, INC. | $176.60 | 2019-2022 | |
| Allergan, INC. | $169.85 | 2019-2020 | |
| Esperion Therapeutics, INC. | $144.12 | 2020-2025 | Nexletol |
| Exact Sciences Corporation | $134.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $109.31 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.62 | 2022-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $81.85 | 2019-2022 | |
| Abbott Laboratories | $81.84 | 2020-2023 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $80.92 | 2022-2023 | Yupelri |
| Alkermes, INC. | $70.48 | 2023-2025 | Lybalvi, Vivitrol |
| Biohaven Pharmaceutical Holding Company Ltd. | $58.95 | 2022 | |
| Xeris Pharmaceuticals, INC. | $54.86 | 2021-2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $54.38 | 2022-2023 | Quviviq |
| Sumitomo Pharma America, INC. | $50.21 | 2024-2025 | Gemtesa |
| Daiichi Sankyo INC. | $49.92 | 2022 | |
| Dexcom, INC. | $49.55 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $48.68 | 2024-2025 | Camzyos, Eliquis |
| Abiomed | $44.49 | 2024 | Impella |
| Verona Pharma, INC. | $38.80 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $38.19 | 2025 | Zenpep |
| Sunovion Pharmaceuticals INC. | $37.66 | 2019 | |
| Genentech USA, INC. | $36.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.01 | 2019-2021 | |
| Lucid Diagnostics INC. | $26.98 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $22.33 | 2022 | |
| Gilead Sciences, INC. | $18.44 | 2021 | |
| Biogen, INC. | $18.38 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.01 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $16.37 | 2019 | |
| Becton, Dickinson and Company | $15.57 | 2019 | |
| Mdd US Operations, LLC | $15.04 | 2020 | |
| Medtronic, INC. | $14.01 | 2023 | Kyphon Express II Kyphopak Tray |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Byers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.